Valued at USD 7.28 billion in 2024, the neurovascular devices market is projected to reach USD 7.70 billion in 2025 and USD 12.84 billion by 2034, growing at a CAGR of 5.9% during the forecast period 2025–2034. Neurovascular devices are medical tools designed to diagnose and treat conditions affecting the brain's blood vessels, including ischemic stroke, intracranial aneurysms, arteriovenous malformations, and stenosis. Growth is supported by demographic aging and expanding adoption of minimally invasive treatment approaches. North America was the largest market in 2024.

Aging Population Drives Neurovascular Demand

The rise in the global elderly population is leading to a higher incidence of neurovascular disorders. According to the WHO, the share of people aged 60 and above in the South-East Asia Region is projected to rise from 12.2% in 2024 to 22.9% by 2050. Age-related changes such as reduced vascular elasticity and increasing atherosclerosis risk add to the disease burden, and healthcare systems are focusing on early detection and intervention to reduce morbidity and mortality among older patients.

Minimally Invasive Neurovascular Procedures Gain Share

The shift toward minimally invasive neurovascular procedures is accelerating as providers and patients seek safer treatment with shorter recovery times. The WHO 2024 report found that more than 80% of neurological deaths and health loss occur in low- and middle-income countries. Mechanical thrombectomy, aneurysm coiling, and flow diversion reduce surgical trauma and hospital stay while maintaining high efficacy, and favorable reimbursement in developed markets further fuels demand.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/neurovascular-device-market

Embolization Devices Dominate the Device Type Segment

The embolization devices segment dominated in 2024, driven by widespread use in aneurysm occlusion and arteriovenous malformation treatment. Coils and liquid embolics effectively block abnormal blood flow, reducing the risk of rupture and associated complications. The segment's dominance is supported by its minimally invasive nature, which allows precise deployment and faster recovery, and rising awareness of early intervention is expected to sustain its position.

Ischemic Stroke and Mechanical Thrombectomy

Ischemic stroke dominated by application in 2024, reflecting the high global prevalence of stroke cases requiring urgent intervention. Mechanical thrombectomy and aspiration techniques have become standard treatment approaches, reducing disability and improving survival, and mechanical thrombectomy devices remove clots and restore blood flow when used within the treatment window. Flow diverters redirect blood away from aneurysms to support vessel wall healing, while embolic coils are applied for aneurysm occlusion to prevent rupture. In July 2025, Imperative Care received FDA clearance for its Zoom 7X catheter for acute ischemic stroke, featuring a pre-shaped tip to improve navigation and clot removal.

Regional Analysis: North America, Europe, and Asia Pacific

North America dominated in 2024, supported by advanced healthcare infrastructure across the U.S. and Canada and favorable reimbursement frameworks. The U.S. held the largest regional share; according to the CDC, over 795,000 people in the U.S. experience a stroke each year, and about 87% are ischemic strokes. In Europe, Germany, France, and the UK lead adoption, and in June 2025 Philips launched SmartCT in Europe after CE marking, enabling real-time 3D imaging for faster stroke diagnosis.

Asia Pacific is projected to grow at the fastest CAGR, driven by government healthcare infrastructure initiatives and rising awareness of early stroke intervention. In China, the population aged 60 and above is projected to exceed 400 million by 2035, over 30% of the total population compared with 21% in 2025.

Key Players in the Neurovascular Devices Market

The neurovascular devices is moderately competitive. Major companies include Medtronic plc, Stryker Corporation, Penumbra, Inc., Terumo Corporation, MicroPort Scientific Corporation, Balt Group SAS, Kaneka Corporation, Johnson & Johnson, Acandis GmbH, phenox GmbH, Rapid Medical Ltd., and Asahi Intecc Co., Ltd. In January 2025, Radical Catheter Technologies received FDA 510(k) clearance for its 8-F neurovascular catheter, and in February 2025 Johnson & Johnson MedTech launched the CEREGLIDE 92 catheter system in the U.S. High device costs and limited availability of skilled neurointerventional specialists remain restraints.

More Trending Latest Reports By Polaris Market Research:

laundry-detergent-market

outsourced-semiconductor-assembly-and-test-market

global-paints-and-coatings-market

radiotheranostics-market

glp-1-analogues-market

multiparameter-patient-monitoring-market

vanillin-market

warehouse-automation-market

alginate-market